Iatrogenic Osteoporosis

A.P. Barbosa, M.R. Mascarenhas

Abstract


The literature review provides information on the major calcium-regulating hormones and their role in the regulation of bone remodeling. These processes are also influenced by sex steroids, growth hormone, insulin, cortisol, thyroid hormones and various local growth factors. In this regard, osteopenia and osteoporosis are closely linked to a number of endocrine diseases, some of which are common (diabetes mellitus, hyperthyroidism), others — quite rare (endogenous hypercortisolism). Osteoporosis associated with diabetes, steroid osteoporosis, osteoporosis in thyroid function abnormality are considered in detail. It is emphasized that timely diagnosis and adequate treatment of endocrine diseases associated with a decrease in bone mineral density, contribute to slowing or stopping bone loss, normalization of bone remodeling, enables to reduce the incidence of fractures and to improve the quality of life of the patient.


Keywords


osteoporosis; risk factors

Full Text:

PDF

References


Canalis E., Mazziotti G, Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy // Osteoporos. Int. — 2007. — Vol. 18. — P. 1319-1328.

Manolagas S.C. Corticosteroids and fractures: a close encounter of the third cell kind // J. Bone Miner. Res. — 2000. — Vol. 15. — P. 1001-1005.

Chee C., Sellahewa L., Pappachan J.M. Inhaled corticosteroids and bone health // The Open Respiratory Medicine Journal. — 2014. — Vol. 8, Suppl. 1. — P. 85-92.

Tuck S.P., Francis R.M. Testosterone, bone and osteoporosis // Frontiers of Horm. Res. — 2009. — Vol. 37. — P. 123-132.

Eastell R., Hannon R.A., Cuzick J. et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrazole, Tamoxifen, Alone or in Combination (ATAC) trial // J. Bone Min. Res. — 2006. — Vol. 21. — P. 1215-1223.

Greenspan S.L. Approach to the prostate cancer patient with bone disease // J. Clin. Endocrinol. Metab. — 2008. — Vol. 93. — P. 2-7.

Shahinian V.B., Kuo Y.F., Freeman J.L. et al. Risk of fracture after androgen deprivation for prostate cancer // N. Engl. J. Med. — 2005. — Vol. 352. — P. 154-164.

Shahinian V.B., Kuo Y., Freeman J.L. et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate cancer // Cancer. — 2005. — Vol. 103. — P. 1615-1624.

Mittan D., Lee S., Miller E. et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs // J. Clin. Endocrinol. Metab. — 2002. — Vol. 87. — P. 3656-

Bazelier M.T., Vestergaard P., Gallagher A.M. et al. Risk of fracture with thiazoledinediones: disease or drugs? // Calcif. Tissue Int. — 2012. — Vol. 90. — P. 450-457.

Warden S.J., Robling A.G., Haney E.M. et al. The emer­ging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5) // Bone. — 2010. — Vol. 46. — P. 4-12.

Bliziotes M. Update in serotonin and bone // J. Clin. Endocrinol. Metab. — 2010. — Vol. 95. — P. 4124-4132.

Spangler L., Scholes D., Brunner R.L. et al. Depressive symptoms, bone loss and fractures in postmenopausal women // J. Gen. Intern. Med. — 2008. — Vol. 23. — P. 567-574.

Chau K., Atkinson S., Taylor V. Are selective serotonin reuptake inhibitors a secondary cause of low bone density? // J. Osteop. — 2012.

Wu Q., Wenchun Q., Crowell M.D. et al. Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies // J. Bone Min. Res. — 2013. — Vol. 28. — P. 753-762.

Haney E.M., Warden S.J., Bliziotes M.M. The effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening // Bone. — 2010. — Vol. 46. — P. 13-17.

Motyl K.J., Dick-de-Paula I., Maloney A.E. et al. Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain // Bone. — 2012. — Vol. 50. — P. 490-498.

Bassett J.H., Williams G.R. The molecular actions of thyroid hormone in bone // Trends in Endocrinol. and Metab. — 2003. — Vol. 14. — P. 356-364.

Abe E., Marians R.C., Yu W. et al. TSH is a negative regulator of skeletal remodeling // Cell. — 2003. — Vol. 115. — P. 151-162.

Turner M., Camacho X., Fischer H. et al. Levothyro-xine dose and risk of fractures in older adults: nested case-control study // Br. Med. J. — 2011. — Vol. 342. — P. 1-9.

Barbosa A.P., Mascarenhas M.R., Simões V. et al. Subcli­nical and overt hyperthyroidism effect on BMD and soft tissue composition of elderly women // J. Bone Min. Res. — 2012. — S. 427.

Barbosa A.P., Mascarenhas M.R., Silva C.F. et al. Prevalence of silent vertebral fractures detected by vertebral fracture assessment in young Portuguese men with hyperthyroidism // Eur. J. Endocrinol. — 2015. — Vol. 172. — P. 189-194.

Roux C., Briot K., Gossec L. et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole // Calcif. Tissue Int. — 2009. — Vol. 84. — P. 13-19.

Yu E.W., Blackwell T., Ensrud K.E. et al. Acid-Suppressive medications and risk of bone loss and fractures in older adults // Calcif. Tissue Int. — 2008. — Vol. 83. — P. 251-259.

Solomon D.H., Diem S. J., Ruppert K. et al. Bone mi­neral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study // J. Bone Min. Res. — 2014. — Vol. 30. — P. 232-239.

Vestergaard P. Proton pump inhibitors, histamine H2 receptor antagonists and other antacid medications and the risk of fracture // Calc. Tissue Int. — 2006. — Vol. 79. — P. 76-83.

Yang Y., Lewis J.D., Epstein S. et al. Long-term proton pump inhibitor therapy and risk of hip fracture // JAMA. — 2006. — Vol. 296. — P. 2947-2953.

Yu E.W., Bauer S.R., Bain P.A. et al. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international stu­dies // Am. J. Med. — 2011. — Vol. 124. — P. 519-526.

Hileman C.O., Labbato D.E., Storer N.U. et al. Is bone loss linked to chronic inflammation in antiretroviral-naïve HIV-infec­ted adults? // AIDS. — 2014. — Vol. 28. — P. 1759-1767.

Cotter E.J., Chow N., Powderly W.G. et al. HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex vivo // AIDS Res. Hum. Retroviruses. — 2011. — Vol. 150. — P. 67-78.

Shiau S., Broun E.C., Arpadi S.M. et al. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis // AIDS. — 2013. — Vol. 27. — P. 1949-1957.

Bedimo R., Maalouf N.M., Zhang S. et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents // AIDS. — 2012. — Vol. 26. — P. 825-831.

Grigsby I.F., Pham L., Mansky L.M. et al. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss // Biochem. Biophys. Res. Commun. — 2010. — Vol. 394. — P. 48-53.

Malizia A.P., Cotter E., Chew N. et al. HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts // AIDS Res. Hum. Retroviruses. — 2007. — Vol. 23. — P. 243-250.

Brown T.T., McComsey G.A. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D // Antivir. Ther. — 2010. — Vol. 15. — P. 425-429.

Carbone L.D., Johnson K.C., Bush A.J. et al. Loop diuretic use and fracture in postmenopausal women: findings from the Wo­men’s Health Initiative // Arch. Int. Med. — 2009. — Vol. 169. — P. 132-140.

Vestergaard P. Epilepsy, osteoporosis and fracture risk — a meta-analysis // Acta Neurol. Scand. — 2005. — Vol. 112. — P. 277-286.

Omdahl J.L., Morris H.A., May B.K. Hydroxilase enzymes of the vitamin D pathway: expression, function and regulation // Ann. Rev. Nutr. — 2002. — Vol. 22. — P. 139-166.

Fitzpatrick L.A. Pathophysiology of bone loss in patients receiving anticonvulsant therapy // Epilepsy Behav. — 2004. — Vol. 5. — S. 3-15.

Muir J.M., Andrew M., Hirsh J. et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo // Blood. — 1996. — Vol. 88. — P. 1314-1320.

Irie A., Takami M., Kubo H. et al. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity // Bone. — 2007. — Vol. 41. — P. 165-174.

Jamal S.A., Browner W.S., Bauer D.C. et al. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group // Ann. Int. Med. — 1998. — Vol. 128. — P. 829-832.

Fusaro M., Carbonare L.D., Dusso A. et al. Differential effects of dabigatran and warfarin on bone volume and structure in rats with normal renal function // PLoS One. — 2015. — Vol. 10.

Solayar G.N., Walsh P.M., Mulhall K.J. The effect of a new direct factor Xa inhibitor on human osteoblasts: an in vitro study comparing the effect of rivaroxaban with enoxaparin // BMC Musculoskelet. Disord. — 2011. — Vol. 12. — P. 247.

Maalouf N.M., Shane E. Osteoporosis after solid organ transplantation // J. Clin. Endocrinol. Metab. — 2005. — Vol. 90. — P. 2456-2465.

Epstein S., Shane E., Bilezikian J.P. Organ transplantation and osteoporosis // Curr. Opin. Rheumatol. — 1995. — Vol. 7. — P. 255-261.

Zhang R., Chouhan K.K. Metabolic bone diseases in kidney transplant recipients // World J. Nephrol. — 2012. — Vol. 1. — P. 127-133.

Pitts C., Kearns A. Update on medications with adverse ske­letal effects // Mayo Clin. Proc. — 2011. — Vol. 86. — P. 338-343.

Mazziotti G., Canalis E., Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications // Am. J. Med. — 2010. — Vol. 123. — P. 877-884.




DOI: https://doi.org/10.22141/2224-0721.8.72.2015.72339

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru